PCSK9 inhibition: A promise fulfi lled?

Cleveland Clinic Journal of Medicine

Volumn 83, Issue , 2016, Pages 36-44

  White, Khendi ^a   Mohan, Chaitra ^a   Rocco, Michael ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Section of Preventive Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS-962476; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROGOL DERIVATIVE; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; PROTEIN;

ANTAGONISTS AND INHIBITORS; HUMAN; HYPERCHOLESTEROLEMIA;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; POLYETHYLENE GLYCOLS; PROPROTEIN CONVERTASE 9; PROTEINS;

EID: 85026614597     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/CCJM.83.S2.05     Document Type: Article

References (57)

1. 1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383–1389.
2. 2. Sacks FM, Pfeiffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335:1001–1009.
3. 3. Schwartz GG, Olsson AG, Ezekowitz MD, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711–1718.
4. 4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results (reduction in incidence of coronary heart disease). JAMA 1984; 251:351–364.
5. 5. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109(suppl 1):III39–III43.
6. 6. Stone N, Robinson J, Lichtenstein A, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(suppl 2):S1–S45.
7. 7. Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 2015; 9:129–169.
8. 8. Jarcho JA, Keaney JF Jr. Proof that lower is better–LDL cholesterol and IMPROVE-IT. N Engl J Med 2015; 372:2448–2450.
9. 9. Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387–2397.
10. 10. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267–1278.
11. 11. de Ferranti S, Rodday AM, Mendelson M, et al. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation 2016; 133:1067–1072.
12. 12. Perez de Isla L, Alonso R, Watts GF, et al; SAFEHEART investigators. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. J Am Coll Cardiol 2016; 67:1278–1285.
13. 13. Unni SK, Quek RGW, Biskupiak J, et al. Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States. J Clin Lipidol 2016; 10:63–71.
14. 14. Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheum 2010; 22:644–650.
15. 15. AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255–2267.
16. 16. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/ laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34:1279–1291.
17. 17. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563–1574.
18. 18. Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366:1849–1861.
19. 19. Kaur N, Pandey A, Negi H, et al. Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression. PLoS One 2014; 9:e94585.
20. 20. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109–2122.
21. 21. Rader D, Kastelein J. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014; 129:1022–1032.
22. 22. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154–156.
23. 23. Verbeek R, Stoekenbroek RM, Hovingh GK. PCSK9 inhibitors: novel therapeutic agents for the treatment of hypercholesterolemia. Eur J of Pharm 2015; 763(Pt A):38–47.
24. 24. Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci USA 2009; 106:9546–9547.
25. 25. Abifadel M, Rabès J-P, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009; 30:520–529.
26. 26. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264–1272.
27. 27. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybærg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Am Coll Cardiol 2010; 55:2833–2842.
28. 28. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study. Eur Heart J 2015; 36:2446–2453.
29. 29. Victor RG, Haley RW, Willett DL, et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004; 93:1473–1480.
30. 30. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007; 48:763–767.
31. 31. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Comm 2008; 375:69–73.
32. 32. Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 2014; 65:417–431.
33. 33. Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J 2009; 419:577–584.
34. 34. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal anti-body to PCSK9 on LDL cholesterol. N Eng J Med 2012; 366:1108–1118.
35. 35. Koren MJ, Lundqvist P, Bolognese M, et al; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63:2531–2540.
36. 36. Blom DJ, Hala T, Bolognese M, et al; DESCARTES investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370:1809-1819.
37. 37. Raal FJ, Stein EA, Dufour R, et al; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2014; 385:331–340.
38. 38. Robinson JG, Nedergaard BS, Rogers WJ, et al; LAPLA C-2 Investigators. Effect of evolocumab or ezetimibe added to moderate or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014; 311:1870–1882.
39. 39. Stroes E, Colquhoun D, Sullivan D, et al; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63:2541–2548.
40. 40. Nissen SE, Stroes E, Dent-Acosta RE, et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance, the GAUSS-3 randomized clinical trial. JAMA 2016; 315:1580–1590.
41. 41. Trial assessing long term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG). U.S. National Institutes of Health website. https://clinicaltrials.gov/ct2/show/NCT-1624142. Updated June 25, 2015. Accessed October 23, 2016.
42. 42. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015; 36:2996–3003.
43. 43. Efficacy and safety of alirocumab (SAR236553/REGN727) versus placebo on top of lipid-modifying therapy in patients with heterozygous familial hypercholesterolemia; the ODYSSEY HIGH FH trial. U.S. National Institutes of Health website. https://clinicaltrials.gov/ct2/show/NCT01617655. Updated September 27, 2016. Accessed October 23, 2016.
44. 44. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J 2015; 169:906–915.
45. 45. Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II). U.S. National Institutes of Health website. Updated June 23, 2016. https://clinicaltrials.gov/ct2/show/NCT01644188. Accessed October 23, 2016.
46. 46. Roth EM, Moriarty P, Bergeron J, et al; ODYSSEY CHOICE I investigators. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis 2016, doi: 10.1016/j.atherosclerosis.2016.08.043.
47. 47. Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II). U.S. National Institutes of Health website. https://clinicaltrials.gov/ct2/show/NCT02023879. Updated November 2, 2015. Accessed October 23, 2016.
48. 48. Monthly and twice monthly subcutaneous dosing of PF-04950615 (RN316) in hypercholesterolemic subjects on a statin. U.S. National Institutes of Health website. https://clinicaltrials.gov/ct2/results?term=NCT01592240. Updated October 14, 2014. Accessed October 23, 2016.
49. 49. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 2015; 13:123.
50. 50. Sabatine MS, Giugliano RP, Wiviott SD, et al; OSLER Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500–1509.
51. 51. Robinson JG, Farnier M, Krempf M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1489–1499.
52. 52. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of pro-protein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015; 163:40–51.
53. 53. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). U.S. National Institutes of Health website. https://clinicaltrials.gov/ct2/show/NCT01764633. Updated July 26, 2016. Accessed October 23, 2016.
54. 54. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab. U.S. National Institutes of Health website. https://clinicaltrials.gov/ct2/show/NCT01663402. Updated October 23, 2016. Accessed September 13, 2016.
55. 55. The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1). U.S. National Institutes of Health website. https://clinicaltrials.gov/ct2/show/NCT01975376. Updated September 22, 2016. Accessed October 23, 2016.
56. 56. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). U.S. National Institutes of Health website. https://clinicaltrials.gov/ct2/show/NCT01975389. Updated July 26, 2016. Accessed October 23, 2016.
57. 57. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al; Writing Committee. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 2016; 68:92–125.